Anti-Chikungunya Virus [Clone CHKV-35] — Recombinant in vivo Functional Grade - 250 µg

Primary Monoclonal Antibodies>Infectious Diseases|Monoclonal Antibodies|Recombinant Antibodies

Standard Overnight on Blue Ice.

Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes epidemics globally and has been declared a notable disease by the CDC1, 2. Symptoms include high fever, myalgia, rash, and severe polyarthritis which can persist for long after acute infection. CHIKV is an enveloped virus with an 11.8-kb single-stranded, positive-sense RNA genome with two open reading frames3, 4. There are three main genotypes, having 95.2 to 99.8% amino acid identity: Asian, West African, and East/Central/South African (ECSA). The mature CHIKV virion is comprised of a nucleocapsid protein C and two glycoproteins, E1 and E25. E1 participates in virus fusion. E2 functions in attachment to cells. E1 and E2 form 80 trimeric spikes on the virus surface6. Co-circulation of CHIKV with other arboviruses, such as dengue, Zika, Mayaro, and yellow fever, occurs in many countries, posing significant difficulties for diagnosis2. Monoclonal antibodies (MAb) can be used both for diagnosis7 and as a therapeutic agent5, 8, 9. CHIKV can be rapidly detected by an immunochromatographic assay using MAbs against the CHIKV envelope protein7. CHKV-35 was generated from peripheral blood mononuclear cells from an immune donor by Epstein-Barr Virus transformation followed by hybridoma generation10. CHKV-35 binds to and neutralizes CHIKV vaccine strain 181/25.

≥ 5.0 mg/ml

The E2 Envelope protein is expressed on the surface of the Chikungunya Virus

Anti-Chikungunya Virus, CHKV-35, CHKV